Tesamorelin in the research literature: a stabilized GHRH analog and how it is studied
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the 44-residue hypothalamic peptide, with a single chemical modification at the N-terminus that protects it from the enzyme that normally destroys GHRH within minutes. It is unusual among research peptides in having a well-documented pharmacology and a regulated pharmaceutical history, which makes the line between the medicine and the research reagent important to draw. This guide covers the structure, the receptor biology, what has been studied, and how a 44-residue peptide is handled. For laboratory research use only.
What tesamorelin is
Human GHRH is secreted by the hypothalamus and acts on the GHRH receptor on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of growth hormone. The native 44-residue peptide, GHRH(1-44)-NH2, is cleaved by dipeptidyl peptidase-4 (DPP-4) between residues 2 and 3 almost immediately in plasma, which limits its usefulness as a research tool. Tesamorelin is GHRH(1-44)-NH2 with a trans-3-hexenoyl group attached to the N-terminal tyrosine. The added group blocks DPP-4 cleavage, extending the peptide’s half-life while preserving full activity at the GHRH receptor. It was developed by Theratechnologies in Canada in the 1990s and 2000s.
| Structure | (trans-3-hexenoyl)-GHRH(1-44)-NH2; 44 amino acids, C-terminal amide |
| Also known as | TH9507, hexenoyl-GHRH(1-44), tesamorelin acetate (salt form) |
| CAS number | 218949-48-5 |
| Molecular formula / weight | C221H366N72O67S · ≈ 5,135.9 g/mol |
| Target | GHRH receptor (GHRH-R), a class B G-protein-coupled receptor |
| Oxidation-sensitive residues | One methionine (position 27) |
| Solubility | Water, bacteriostatic water |
What the literature has studied
Receptor pharmacology
Tesamorelin binds and activates the GHRH receptor with potency comparable to native GHRH, stimulating cAMP production and growth-hormone release in pituitary cell preparations. Its defining property over the native peptide is stability: resistance to DPP-4 gives it a plasma half-life of tens of minutes rather than a few, so that a single exposure produces a sustained rather than momentary receptor stimulus. This is the basis for its use as a GHRH-receptor tool compound in pituitary and endocrine research.
Growth-hormone axis studies
Because it works through the pituitary, tesamorelin produces a physiological pattern of growth-hormone release, pulsatile and subject to normal feedback by IGF-1 and somatostatin, rather than the continuous exposure produced by administering growth hormone itself. Much of the research interest, in animals and in the clinical program, has been in whether that distinction matters for downstream effects on body composition and metabolism. That question is studied with the pharmaceutical product in defined patient groups and is not something a research reagent can address.
Clinical development
Tesamorelin is one of the few peptides in a research catalog to have completed full clinical development: a pharmaceutical formulation has been approved by regulators for a specific clinical indication in a defined patient population, with published phase 3 trials. That history is why the pharmacology is well characterized. It is also why the distinction matters: the approved product is a regulated medicine with its own manufacturing, labeling and prescribing framework, and its clinical data describe that product in those patients. A research-grade reagent is supplied for in-vitro and preclinical work only, and nothing in the clinical literature transfers to it.
What the literature has not shown
Outside the approved indication and patient group, effects in people have not been established. The research reagent has no clinical data of its own. Long-term outcomes of chronic GHRH-receptor stimulation are the subject of ongoing study in the clinical setting and are not characterized for any other use. Suppliers describing the peptide in terms of general human benefits are describing the medicine’s data, out of context, or nothing at all.
How tesamorelin is supplied for research
Quantum Peptides supplies tesamorelin, 5 mg lyophilized powder. Each lot is tested by an independent US laboratory to a minimum of 99% purity by HPLC, with mass-spectrometry identity (expected mass ≈ 5,135.9), and the lot certificate is linked on the product page. For a 44-residue peptide with a methionine, two things are worth checking on the certificate: that the observed mass matches without a +16 Da oxidized peak of significant size, and that the chromatogram shows a single main peak, since a chain this long has many possible deletion sequences that a poor synthesis leaves behind. See peptide purity explained and how to read a certificate of analysis.
Reconstitution and handling
Tesamorelin dissolves readily in water or bacteriostatic water. As an example, 5 mg reconstituted with 1 mL gives 5 mg/mL, which is about 0.97 mM given the high molecular weight; the peptide calculator works out the volume for any concentration, and the reconstitution guide covers the procedure. Two handling points follow from the structure. First, the methionine at position 27 oxidizes in solution, so prepare solutions fresh where possible, keep them cold (2–8 °C) and dark, and freeze single-use portions rather than repeatedly opening one vial. Second, long peptides foam and can aggregate if shaken; add the diluent slowly down the vial wall and swirl. Store the lyophilized powder at −20 °C, desiccated and protected from light; see peptide storage and shelf life and bacteriostatic vs sterile water.
Frequently asked questions
What is tesamorelin?
A synthetic analog of human growth-hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoyl group on the N-terminus that protects it from DPP-4 cleavage. It acts at the GHRH receptor.
What is the molecular weight and CAS number of tesamorelin?
About 5,135.9 g/mol (C221H366N72O67S); CAS 218949-48-5.
How is tesamorelin different from GHRH?
Identical in sequence; the only difference is the hexenoyl group at the N-terminus, which blocks the enzyme (DPP-4) that cleaves native GHRH within minutes, giving the analog a usable half-life.
Is tesamorelin oxidation-sensitive?
Yes, moderately: it has one methionine (position 27). Prepare solutions fresh, keep them cold and dark, and divide into single-use portions.
Has tesamorelin been approved as a medicine?
A pharmaceutical formulation has regulatory approval for a specific indication in a defined patient group. Those data describe that product and those patients; they do not apply to a research reagent, which is supplied for in-vitro and preclinical use only.
Can I buy tesamorelin for human use?
No. Quantum Peptides products are supplied for in-vitro and preclinical laboratory research only, not for human or veterinary use.
References
- Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation. 1989.
- Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology. 2007.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007.
More research guides
Quantum Peptides supplies lyophilized research peptides for in-vitro and preclinical laboratory research only. Products are not for human or veterinary use. This guide summarizes published literature and is not guidance on administration of any kind.